目的:观察赖诺普利对血压正常、尿蛋白正常的糖尿病患者非增殖性糖尿病视网膜病变(NPDR)进展的影响.方法:将43例血压正常的1型糖尿病伴非增殖性视网膜病变的患者随机分为2组,赖诺普利组22例(赖诺普利,口服10mg/d)；对照组21例(维生素C片,口服50 mg/d).根据眼底照片和眼底荧光造影评估视网膜病变分级(除外增殖性视网膜病变).观察治疗1年后视网膜病变的变化.结果:视网膜病变好转,赖诺普利组40.9％(9/22例),对照组9.5％(2/21例)；视网膜病变进展,赖诺普利组13.6％(3/22例)；对照组42.8％(9/21例).与对照组比较,赖诺普利组明显减慢了视网膜病变进展,有统计学意义(P＜0.05).结论:赖诺普利可减缓1型糖尿病患者非增殖性视网膜病变的进程,不依赖于血压变化.%Objective:To observe the effect of lisinopril on non -proliferative diabetic retinopathy (NPDR) in patients with normotensive and normoalbuminuria type 1 diabetes. Methods; A total of 43 NPDR patients with normotensive and normoalbuminuria type 1 diabetes were randomly divided into 2 groups: lisinopril group (10 mg daily, n=22) and control group( vitamin C,50 mg daily, n =21). Retinopathy was classified according to the fundus photograph and fundus fluorescein angiography (except proliferative disease). The change of retinopathy was observed in 2 groups after 1 year. Results; The improvement rate of retinopathy in lisinopril group and control group was 40. 9% (9/22) and 9. 5% (2/21) respectively (P < 0. 05 ) , and the progression rate was 13. 6% (3/22) and 42. 8% (9/21) respectively (P < 0. 05). Conclusion: The lisinopril may decrease retinopathy progression in type 1 diabetes patients with NPDR, independent of effect of systemic blood pressure.
展开▼
